Ignite Creation Date:
2025-12-24 @ 10:03 PM
Ignite Modification Date:
2025-12-30 @ 3:22 PM
Study NCT ID:
NCT06475235
Status:
RECRUITING
Last Update Posted:
2025-07-24
First Post:
2024-06-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Sponsor:
Dana-Farber Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-10-18
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-06-20
First Submit QC Date:
None
Study First Post Date:
2024-06-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-21
Last Update Post Date:
2025-07-24
Last Update Post Date Type:
ACTUAL